ADMA BIOLOGICS INC (NASDAQ:ADMA) has been identified as a high-growth momentum stock that aligns with Mark Minervini’s Trend Template. The company, a biopharmaceutical firm specializing in plasma-derived biologics, demonstrates strong technical and fundamental characteristics that make it a compelling candidate for growth-focused investors.
Why ADMA Fits the Minervini Trend Template
Minervini’s strategy focuses on stocks with strong upward momentum, confirmed by key technical indicators. ADMA meets these criteria:
- Price Above Key Moving Averages: The stock trades above its 50-day ($20.82), 150-day ($19.08), and 200-day ($18.78) moving averages, indicating sustained bullish momentum.
- Rising Moving Averages: Both the 150-day and 200-day MAs are trending upward, reinforcing long-term strength.
- Relative Strength: With a ChartMill Relative Strength (CRS) score of 95.42, ADMA outperforms 95% of stocks, a key trait for Minervini-style leaders.
- Price Performance: The stock is up 103% over the past year and is trading within 16% of its 52-week high ($25.67), showing strong momentum.
High Growth Fundamentals
ADMA’s financials reflect accelerating growth, a critical factor for high-growth investors:
- Earnings Growth: EPS surged 2,750% year-over-year (TTM), with recent quarterly growth of 37.5%.
- Revenue Growth: Sales increased 62.2% (TTM), with consistent quarterly growth above 40%.
- Profit Margins: The company reported a trailing twelve-month profit margin of 46.35%, a significant improvement from prior years.
- Estimate Revisions: While next-year EPS estimates have seen slight downward revisions (-4.69%), revenue forecasts remain positive (+5.69%).
Technical Outlook
ADMA’s technical rating of 10/10 highlights its strong trend, though the current setup rating of 5 suggests waiting for a consolidation before entry. Key support levels are found at $20.18-$20.31 and $19.20, providing potential downside protection.
Our High Growth Momentum + Trend Template screener lists more stocks with similar growth and momentum traits.
For a deeper technical analysis, review the full ADMA technical report.
Disclaimer
This is not investment advice. Always conduct your own research and consider risk management before making investment decisions.
